In the past week, VBIV stock has gone up by 13.12%, with a monthly gain of 10.22% and a quarterly surge of 10.69%. The volatility ratio for the week is 4.36%, and the volatility levels for the last 30 days are 5.62% for VBI Vaccines Inc. The simple moving average for the last 20 days is 11.36% for VBIV stock, with a simple moving average of -28.18% for the last 200 days.
Is It Worth Investing in VBI Vaccines Inc. (NASDAQ: VBIV) Right Now?
Moreover, the 36-month beta value for VBIV is 1.91. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VBIV is 22.28M and currently, short sellers hold a 1.36% of that float. On April 02, 2024, VBIV’s average trading volume was 124.18K shares.
VBIV) stock’s latest price update
VBI Vaccines Inc. (NASDAQ: VBIV) has seen a rise in its stock price by 5.21 in relation to its previous close of 0.62. However, the company has experienced a 13.12% gain in its stock price over the last five trading sessions. Market Watch reported 2023-09-27 that VBI Vaccines Inc. said Wednesday the first clinical data from a Phase I trial of a pan-coronavirus vaccine candidate produced broad and durable protection against variants of concern.
Analysts’ Opinion of VBIV
Many brokerage firms have already submitted their reports for VBIV stocks, with Raymond James repeating the rating for VBIV by listing it as a “Outperform.” The predicted price for VBIV in the upcoming period, according to Raymond James is $2 based on the research report published on November 11, 2022 of the previous year 2022.
Jefferies, on the other hand, stated in their research note that they expect to see VBIV reach a price target of $6, previously predicting the price at $7. The rating they have provided for VBIV stocks is “Buy” according to the report published on December 29th, 2021.
Jefferies gave a rating of “Buy” to VBIV, setting the target price at $7 in the report published on February 25th of the previous year.
VBIV Trading at 6.34% from the 50-Day Moving Average
After a stumble in the market that brought VBIV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.18% of loss for the given period.
Volatility was left at 5.62%, however, over the last 30 days, the volatility rate increased by 4.36%, as shares surge +15.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.69% upper at present.
During the last 5 trading sessions, VBIV rose by +15.52%, which changed the moving average for the period of 200-days by -73.22% in comparison to the 20-day moving average, which settled at $0.5884. In addition, VBI Vaccines Inc. saw 10.69% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VBIV starting from GILLIS STEVEN, who purchase 609,090 shares at the price of $1.65 back on Jul 10 ’23. After this action, GILLIS STEVEN now owns 1,043,292 shares of VBI Vaccines Inc., valued at $1,004,998 using the latest closing price.
PERCEPTIVE ADVISORS LLC, the 10% Owner of VBI Vaccines Inc., sale 4,251,563 shares at $0.11 during a trade that took place back on Apr 06 ’23, which means that PERCEPTIVE ADVISORS LLC is holding 41,440,729 shares at $467,672 based on the most recent closing price.
Stock Fundamentals for VBIV
Current profitability levels for the company are sitting at:
- -10.83 for the present operating margin
- -0.59 for the gross margin
The net margin for VBI Vaccines Inc. stands at -15.04. The total capital return value is set at -3.73. Equity return is now at value -219.79, with -83.55 for asset returns.
Based on VBI Vaccines Inc. (VBIV), the company’s capital structure generated 0.72 points at debt to capital in total, while cash flow to debt ratio is standing at -1.31. The debt to equity ratio resting at 2.6. The interest coverage ratio of the stock is -20.71.
Currently, EBITDA for the company is -81.82 million with net debt to EBITDA at -0.23. When we switch over and look at the enterprise to sales, we see a ratio of 3.75. The receivables turnover for the company is 23.01for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.65.
Conclusion
To wrap up, the performance of VBI Vaccines Inc. (VBIV) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
